Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.47 USD
Change Today +0.38 / 3.14%
Volume 103.9K
LXRX On Other Exchanges
Symbol
Exchange
LXRX is not on other exchanges.
As of 10:21 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

lexicon pharmaceuticals inc (LXRX) Snapshot

Open
$12.00
Previous Close
$12.09
Day High
$12.50
Day Low
$11.92
52 Week High
08/4/15 - $13.88
52 Week Low
12/15/14 - $5.60
Market Cap
1.3B
Average Volume 10 Days
855.9K
EPS TTM
$-0.99
Shares Outstanding
103.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LEXICON PHARMACEUTICALS INC (LXRX)

Related News

No related news articles were found.

lexicon pharmaceuticals inc (LXRX) Related Businessweek News

No Related Businessweek News Found

lexicon pharmaceuticals inc (LXRX) Details

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human diseases. Its drug development programs include telotristat etiprate, an orally-delivered small molecule drug candidate, which is in Phase III clinical trials for the treatment of carcinoid syndrome. The company’s drug development programs also comprise Sotagliflozin, an orally-delivered small molecule drug candidate that has completed Phase II clinical trials to treat type 1 diabetes; and has completed two Phase II clinical trials to treat type 2 diabetes, as well as for the treatment of type 2 diabetes in patients with renal impairment. In addition, it develops LX1033, an orally-delivered small molecule compound, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound that has completed Phase II clinical trials to treat autoimmune disease; and LX7101, a topically-delivered small molecule compound that has completed Phase I clinical trials for the treatment of glaucoma. Further, the company’s preclinical development programs comprise LX2761, an orally-delivered small molecule compound for the treatment of diabetes. It has license and collaboration agreement with Ipsen Pharma SAS; and drug discovery alliance with Bristol-Myers Squibb Company and Genentech, Inc. The company was founded in 1995 and is headquartered in The Woodlands, Texas.

106 Employees
Last Reported Date: 03/12/15
Founded in 1995

lexicon pharmaceuticals inc (LXRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $431.9K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $534.5K
Executive Vice President of CMC and Supply Op...
Total Annual Compensation: $457.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $445.4K
Compensation as of Fiscal Year 2014.

lexicon pharmaceuticals inc (LXRX) Key Developments

Lexicon Pharmaceuticals, Inc. Announces Positive Results from Phase III Carcinoid Syndrome Study

Ipsen SA has announced that Lexicon Pharmaceuticals, Inc. has announced positive results from the Phase III TELESTAR study designed to evaluate the efficacy and safety of telotristat etiprate for carcinoid syndrome patients with metastatic neuroendocrine tumor, or NET, inadequately controlled by somatostatin analog, or SSAs. Top-line results from the Phase III study show that patients who added telotristat etiprate to the standard of care at both the 250 mg and 500 mg doses experienced a statistically significant reduction from baseline compared to placebo in the average number of daily bowel movements over the 12-week study period (p<0.001), meeting the study's primary endpoint. Claude Bertrand, Executive vice president R&D and Chief Scientific Officer, Ipsen stated: "We are pleased with the positive top-line Phase III results for telotristat etiprate. Should telotristat etiprate be approved, its oral formulation would satisfy an unmet medical need for patients with carcinoid syndrome not adequately controlled with SSAs therapy.

Lexicon Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year of 2015

Lexicon Pharmaceuticals, Inc. provided financial guidance for the full year of 2015. The company continues to expect contractual revenues from existing agreements in 2015 to be around $3 million. The company continue to expect that operating expenses in 2015 will be in the range of $130 million to $140 million. The company now expect 2015 net cash used in operations to be in the range of $140 million to $150 million, which is a decrease from previous guidance of $150 million to $160 million.

Lexicon Pharmaceuticals, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Lexicon Pharmaceuticals, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenues of $376,000 compared with $676,000 for the same period a year ago. Loss from operations was $26,688,000 compared with $26,111,000 for the same period a year ago. Consolidated net loss was $28,074,000 or $0.27 per basic and diluted share compared with $26,028,000 or $0.35 per basic and diluted share for the same period a year ago. For the six months, the company reported total revenues of $2,168,000 compared with $953,000 for the same period a year ago. Loss from operations was $53,215,000 compared with $56,583,000 for the same period a year ago. Consolidated net loss was $56,150,000 or $0.54 per basic and diluted share compared with $56,863,000 or $0.77 per basic and diluted share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LXRX:US $12.47 USD +0.38

LXRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $43.56 USD -0.58
Boston Scientific Corp $16.39 USD -0.14
CR Bard Inc $188.87 USD -1.52
Johnson & Johnson $91.46 USD -1.18
Medtronic PLC $68.74 USD -1.24
View Industry Companies
 

Industry Analysis

LXRX

Industry Average

Valuation LXRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 54.4x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 38.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LEXICON PHARMACEUTICALS INC, please visit www.lexpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.